Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02PHE
|
||||
Former ID |
DCL000489
|
||||
Drug Name |
AZD9668
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Discontinued in Phase 2 | [1], [2] | ||
Company |
AstraZeneca
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C25H22F3N5O4S
|
||||
InChI |
InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)
|
||||
InChIKey |
QNQZWEGMKJBHEM-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
J01DD06
|
||||
SuperDrug CAS ID |
cas=064952972
|
||||
Target and Pathway | |||||
Target(s) | Leukocyte elastase | Target Info | Inhibitor | [3] | |
KEGG Pathway | Transcriptional misregulation in cancer | ||||
Systemic lupus erythematosus | |||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
C-MYB transcription factor network | |||||
Reactome | Collagen degradation | ||||
Degradation of the extracellular matrix | |||||
Activation of Matrix Metalloproteinases | |||||
WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
Human Complement System | |||||
Degradation of collagen | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6476). | ||||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026715) | ||||
REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.